Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)

NCT01544114 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01544114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01544114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2012
Completion date
February 28, 2015
Enrollment
46 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis (jia)